Clinical trial
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
NCT03073603
Study timeline
Study start (actual)2017-04-20Date precision: day
Registry last updated2023-08-16
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosisunresolved
Interventions
Sponsors & collaborators
University of Colorado, Denverlead sponsor
Patient-Centered Outcomes Research Institutecollaborator
National Multiple Sclerosis Societycollaborator
University of Alabama at Birminghamcollaborator
Mapped research locations
New YorkNew York, United States2PhiladelphiaPennsylvania, United States2BostonMassachusetts, United States1Los AngelesCalifornia, United States1St LouisMissouri, United States1MiamiFlorida, United States1NashvilleTennessee, United States1SeattleWashington, United States1ClevelandOhio, United States1PittsburghPennsylvania, United States1ColumbusOhio, United States1PortlandOregon, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03073603 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.